Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $808.6M | $794.6M | $816.9M | $712.3M | $732.1M | $753.3M | $795.7M | $841.1M |
| Cost of revenue | $212.7M | $213.8M | $608.1M | $554.8M | $556.4M | $564.2M | $206.8M | $620.1M |
| Gross profit | $596.0M | $580.8M | $208.8M | $157.5M | $175.7M | $189.1M | $588.9M | $221.0M |
| Gross margin | 73.7% | 73.1% | 25.6% | 22.1% | 24.0% | 25.1% | 74.0% | 26.3% |
| R&D | $67.7M | $70.4M | $72.5M | $71.4M | $65.0M | $70.0M | $81.2M | $76.2M |
| Operating income | $81.0M | $66.1M | $53.0M | $35.0M | $36.8M | $30.4M | $38.7M | $42.8M |
| EBITDA | $116.7M | $104.8M | $111.6M | $86.7M | $85.1M | $32.3M | $102.6M | $96.7M |
| Net income | $46.2M | $46.8M | $37.3M | $18.2M | $32.6M | −$41.1M | $23.9M | $16.1M |
| Net margin | 5.7% | 5.9% | 4.6% | 2.6% | 4.5% | -5.5% | 3.0% | 1.9% |
| EPS (diluted) | 3.65 | 3.70 | 2.95 | 1.44 | 2.58 | -3.26 | 1.90 | 1.28 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds GUERF.
No tracked institution reports a position in GUERF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2014-01-23 | 4-for-1 |
No one on the platform has traded GUERF yet.
| $245M |
| — |
| NWPHFNewron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416M | — |
| OPSSFOpsens Inc. | $2.14 | +0.65% | $247M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.